India issues strict curbs, oversight on stem cell therapy for critical limb ischemia and chronic wounds
The health ministry said there has been “rampant use of this experimental therapy despite limited knowledge of its safety and efficacy” and little evidence to show any clinical benefits.
New Delhi: In a significant move, the Indian government has released strict guidelines to regulate the use of stem cell therapy for microvascular conditions like critical limb ischemia and chronic wounds. According to two senior officials familiar with the matter, the therapy will no longer be administered routinely in clinical settings, but will be permitted only within authorized research trials.
The decision comes from the Union Ministry of Health and has been backed by documents reviewed by Mint. Priyanka Sharma, a journalist at Mint specializing in the Union Ministry of Health and the pharmaceutical industry, reported on the development. With a background in journalism and public health, Sharma has provided clear and honest news on important health topics affecting the entire country.
Sharma's educational credentials include a journalism degree from the Indian Institute of Mass Communication (IIMC) and specialized training in public health from the Public Health Foundation of India. Prior to her current role at Mint, she worked with India Today, The Pioneer, and ANI, and served as a lead consultant for the National Health Authority. Based in New Delhi, Sharma is an avid traveler who enjoys the mountains and regional cuisines, particularly South Indian food.
Written by urgent.news from Live Mint's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
